Lung Cancer
2018 Third Annual Oncology Guide to New FDA Approvals | June 6, 2018
On April 28, 2017, the FDA accelerated the approval of brigatinib (Alunbrig; Takeda Oncology), a new-generation oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib.
May 2018 Vol 9, No 5 | May 22, 2018
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
To be effective, navigators are required to stay up to date on the constantly changing landscape of lung cancer care.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Osimertinib improves progression-free survival by 54% compared with standard first-line therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented at the ESMO 2017 Congress in Madrid.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy, according to results presented at the ESMO 2017 Congress.
Best Practices in Lung Cancer – November 2017 Vol 8 | November 15, 2017
Findings of a randomized study suggest that follow-up CT scans may not be needed every 3 to 6 months during the first 2 years after surgery for patients with non–small cell lung cancer (NSCLC).
November 2017 Vol 8, No 11 | November 14, 2017
According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”
November 2017 Vol 8, No 11 | November 14, 2017
This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.
August 2017 Vol 8, No 8 | August 3, 2017
Nancy Sayegh-Rooney, RN, Pulmonary Nurse Navigator and Certified Tobacco Specialist Counselor at Richmond University Medical Center on Staten Island, New York, leads a 6-week smoking cessation class in the spring and fall that is free and open to the community.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512